The roles of TRIO and F-actin-binding protein in glioblastoma cells
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Hyunji | - |
dc.contributor.author | Kim, Minhee | - |
dc.contributor.author | Park, Jisoo | - |
dc.contributor.author | Tran, Quangdon | - |
dc.contributor.author | Hong, Youngeun | - |
dc.contributor.author | Cho, Hyeonjeong | - |
dc.contributor.author | Park, Sungjin | - |
dc.contributor.author | Hong, Suntaek | - |
dc.contributor.author | Brazil, Derek P. | - |
dc.contributor.author | Kim, Seon-Hwan | - |
dc.contributor.author | Park, Jongsun | - |
dc.date.available | 2020-02-27T11:42:01Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2018-03 | - |
dc.identifier.issn | 1791-2997 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/4016 | - |
dc.description.abstract | TRIO and F-actin-binding protein (TrioBP), which was initially discovered as a binding partner of Trio and F-actin, is a critical factor associated with hearing loss in humans. However, the function of TrioBP in cancer has not been investigated. In the present study, TrioBP expression was indicated to be highly elevated in U87-MG and U343-MG cells. Furthermore, the TrioBP mRNA expression level was markedly increased in U87-MG and U251-MG cells compared with that in cerebral cortex cells, as determined by deep sequencing. Comprehensive analysis of a public TCGA dataset confirmed that TrioBP expression is elevated in patients with glioblastoma. In summary, the present data indicate that TrioBP expression is increased in glioblastoma cell lines and in patients with glioma, suggesting that TrioBP has potential as a diagnostic marker or therapeutic agent for glioma. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | SPANDIDOS PUBL LTD | - |
dc.relation.isPartOf | MOLECULAR MEDICINE REPORTS | - |
dc.subject | NEWLY-DIAGNOSED GLIOBLASTOMA | - |
dc.subject | NUCLEOTIDE EXCHANGE FACTOR | - |
dc.subject | HEARING-LOSS | - |
dc.subject | ANGIOGENESIS | - |
dc.subject | BEVACIZUMAB | - |
dc.subject | MUTATIONS | - |
dc.subject | ENCODES | - |
dc.title | The roles of TRIO and F-actin-binding protein in glioblastoma cells | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000424400000140 | - |
dc.identifier.doi | 10.3892/mmr.2018.8458 | - |
dc.identifier.bibliographicCitation | MOLECULAR MEDICINE REPORTS, v.17, no.3, pp.4540 - 4546 | - |
dc.identifier.scopusid | 2-s2.0-85041174482 | - |
dc.citation.endPage | 4546 | - |
dc.citation.startPage | 4540 | - |
dc.citation.title | MOLECULAR MEDICINE REPORTS | - |
dc.citation.volume | 17 | - |
dc.citation.number | 3 | - |
dc.contributor.affiliatedAuthor | Hong, Suntaek | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | TrioBP | - |
dc.subject.keywordAuthor | cytoskeleton | - |
dc.subject.keywordAuthor | glioma | - |
dc.subject.keywordAuthor | biomarker | - |
dc.subject.keywordPlus | NEWLY-DIAGNOSED GLIOBLASTOMA | - |
dc.subject.keywordPlus | NUCLEOTIDE EXCHANGE FACTOR | - |
dc.subject.keywordPlus | HEARING-LOSS | - |
dc.subject.keywordPlus | ANGIOGENESIS | - |
dc.subject.keywordPlus | BEVACIZUMAB | - |
dc.subject.keywordPlus | MUTATIONS | - |
dc.subject.keywordPlus | ENCODES | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.